Pharmacodynamic monitoring of cyclosporine A in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies

Transplantation

Volumn 82, Issue 10, 2006, Pages 1280-1285

  Sommerer, Claudia ^a   Konstandin, Mathias ^a   Dengler, Thomas ^a   Schmidt, Jan ^a   Meuer, Stefan ^a   Zeier, Martin ^a   Giese, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cyclosporine therapy; Monitoring of immunosuppression; Renal transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TRANSCRIPTION FACTOR NFAT;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CANCER; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; ERYSIPELAS; FEMALE; FOLLOW UP; GENE EXPRESSION; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT; LUNG CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RECURRENT CANCER; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; SEPSIS; SKIN CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; URINARY TRACT INFECTION; VIREMIA; VIRUS INFECTION;

ADULT; AGED; ANALYSIS OF VARIANCE; CYCLOSPORINE; DRUG MONITORING; FEMALE; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFECTION; INTERFERON TYPE II; INTERLEUKIN-2; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; NFATC TRANSCRIPTION FACTORS; POSTOPERATIVE COMPLICATIONS; RECURRENCE;

EID: 33751531164     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000243358.75863.57     Document Type: Article

References (19)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342(9): 605.
2. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78(4): 557.
3. Sommerer C, Hergesell O, Nahm AM, et al. Cyclosporin A toxicity of the renal allograft-a late complication and potentially reversible. Nephron 2002; 92(2): 339.
4. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation-a multicenter investigation in kidney transplant patients. Transplantation 1994; 58(6): 658.
5. Pescovitz MD, Barbeito R. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 2002; 16(5): 378.
6. Morris RG, Russ GR, Cervelli MJ, et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24(4): 479.
7. Di Paolo S, Teutonico A, Schena A, et al. Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: results at 3 years. Am J Kidney Dis 2004; 44(5): 886.
8. Einecke G, Schutz M, Mai I, et al. Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant 2005; 20(7): 1463.
9. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001; 12(4): 828.
10. Kung L, Batiuk TD, Palomo-Pinon S, et al. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant 2001; 1(4): 325.
11. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68(9): 1356.
12. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem 1999; 45(9): 1477.
13. Hartel C, Fricke L, Schumacher N, et al. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin Chem 2002; 48(12): 2225.
14. Giese T, Zeier M, Meuer S. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant 2004; 19 Suppl 4: IV55.
15. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004; 77(3): 339.
16. Clipstone NA,Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357(6380): 695.
17. Pai SY, Fruman DA, Leong T, et al. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood 1994; 84(11): 3974.
18. Sindhi R, LaVia MF, Paulling E, et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen. Transplantation 2000; 69(3): 432.
19. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351(9103): 623.